Catalog Home Page

Advances in inclusion body myositis: genetics, pathogenesis and clinical aspects

Needham, M. and Mastaglia, F.L. (2017) Advances in inclusion body myositis: genetics, pathogenesis and clinical aspects. Expert Opinion on Orphan Drugs, 5 (5). pp. 431-443.

Link to Published Version: http://dx.doi.org/10.1080/21678707.2017.1318056
*Subscription may be required

Abstract

Introduction: Inclusion body myositis is the most common acquired muscle disease affecting older adults. It has an insidious onset with a very specific pattern of muscle involvement, but the aetiopathogenesis is still unknown. Pathologically the combination of inflammatory changes, degenerative changes as well as mitochondrial and nuclear changes are seen, and probably all contribute to the loss of muscle, however the primary abnormality remains a mystery. Treatment is currently supportive, but clinical trials are ongoing and are directed at new targets.

Areas covered: Clinical profile, genetic susceptibility, pathogenesis and treatment

Expert opinion: Understanding the aetiopathogeneis is vital to identify future treatment targets. In addition, understanding the natural history and the roles of biomarkers including the anti-CN1a antibody is vital for designing future clinical trials in IBM, to be properly designed and of sufficient duration to detect clinically significant changes.

Publication Type: Journal Article
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Publisher: Taylor & Francis
Copyright: © 2017 Informa UK Limited
URI: http://researchrepository.murdoch.edu.au/id/eprint/36705
Item Control Page Item Control Page